SI-BONE, Inc. reported results for the quarter ended 2026, with revenue of $56.01M, an improvement versus $48.63M a year earlier, and a reduced net loss and loss per share compared with the prior-year quarter.Financial Highlights¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “loss…
Explore more price target data and ratings for SI-BONE, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for SI-BONE, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not…
Q2 2026 delivered 15% revenue growth, strong operating leverage, and a narrowed net loss, driven by broad-based demand and expanding physician adoption. Guidance was raised, with multiple catalysts ahead, including a new product launch and favorable reimbursement changes.Based on SI-BONE, Inc. [SIB…
Q2 2026 saw 15.2% worldwide revenue growth, record physician engagement, and a 178% improvement in adjusted EBITDA. Updated FY26 guidance projects $231–$233 million in revenue and sustained 79% gross margin, with robust liquidity and strong U.S. market momentum.Original document: SI-BONE, Inc. [SIB…
Q2 2026 saw 15.2% revenue growth, improved net loss, and positive adjusted EBITDA. Guidance for 2026 revenue was raised to $231–$233 million, with strong U.S. and international performance, favorable reimbursement, and new product launches expected to drive further growth.Original document: SI-BONE…
SIBN (SI-BONE, Inc.) is set to announce its Q2'26 results on August 03, after the market closes. The earnings are expected to be disclosed at 4:09 PM ET (8:09 PM UTC).For Q2'26, revenue estimate is 55.27 million USD with EPS (earnings per share) anticipated at (0.15) USD. Learn more details at SIBN…
